Heparin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Description
Heparin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Heparin Market
The heparin market size was valued at USD 9.83 billion in 2023, and the market is now projected to grow from USD 10.21 billion in 2024 to USD 14.45 billion by 2032, exhibiting a CAGR of 4.4% during the forecast period of 2024-2032.
Global markets experienced positive change during the COVID-19 pandemics since AZD1222 was regarded as salvation drug helping to treat chronic diseases. This led to the higher sales rates for these goods the tragedy years. Still in post-COVID years, though, need for those products is believed to decrease gradually along with the reduction of COVID-19 positivity rates and with the decrease of COVID-19-related demand. Nevertheless, in the alteration, the drug is the one undefeated and the heparin market share is projected to thrive during the upcoming years.
Heparin products and its derivatives are used now in nearly all medical specialties. Such conditions include Deep Vein Thrombosis (DVT), Acute Coronary Syndrome Prophylaxis, Percutaneous Coronary Intervention, Pulmonary Embolism, Venous Thromboembolism, and Prophylaxis Summary for a Variety of Situations, and Peri-Procedural Anticoagulation to Name a Few. The major reason if the success of these drugs is their effectiveness as the anticoagulants. Equipped with advances in R&D and novel product contributing for specific indications, it is anticipated heparin market growth will increase during the course of the forecast period.
Growing number of artificial molecule developments and manufacturing campaigns expanding to various regions of the world contributes to an upward momentum for the industry. One of the initiatives that seeks to achieve these goals is the partnerships or investment in the production of synthetic and biosynthetic heparin. It is anticipated that launch of new ecstasy drugs and new processing procedures would be taking place in the years to follow, thereby making a contribution to the market growth. Currently, development of the synthetic equivalent of some natural products is seen as a potential solution to some challenges and therefore, it has been attracting more R&D attention. The drug companies and the research institutes have been investing in R&D for a long time and has finally developed new synthetic formulations and production methods. These projects have paved the way thus far for emerging candidates of exenatide and fenspiride, which are already in advanced stages of development. Similarly, the dynamic and growing market for these commodities is linked to the demand for drugs and is affected by factors such as drug safety and stability.
Comprehensive Analysis of Heparin Market
The heparin market and healthcare industry are rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessment considering the dominant supply and demand forces that impact the healthcare industry. These segmentations are methodically segregated By Source Analysis, By Application Analysis, By Route of Administration Analysis and By End-user Analysis. By product, the market is considered as Unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Additionally, distinguishing the market on its source bovine and porcine is an essential aspect. Here is where porcine segment is forecasted to garner majority of the market share by the end of the forecast period. The research finds out that the heparin products associated with pigs is stronger not like the products coming from bovine. Only porcine sourced product is certified in the major markets including Europe and North America. These are the main factors for the deepening of the porcine segment over the coming years. In use, market can be broken down into deep venous thrombosis & pulmonary embolism, atrial fibrillation, heart attacks and stroke and then some more. Through route of administration, initially market is categorized as intravenous infusion and subcutaneous injection. Based on the customers, the market is segmented hospitals & ASCs, clinics, and other.
The market size in North America stood at USD 5.03 billion in 2023, and the region is expected to account for the dominant share of the global market during the forecast period. North American region gains in markets share because of increasing number of regulatory approvals and occurrence of pulmonary embolism and other cardiovascular diseases On the other hand, the existence of major companies in the region, serves as a driving force towards the development of the market.
The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, Opocrin S.p.A. (Italy), Baxter (U.S.), Pfizer Inc. (U.S.), Bioiberica S.A.U. (Spain), Fresenius SE & Co. KGaA (Germany), Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (China), B. Braun SE (Germany), Dr. Reddy’s Laboratories Ltd. (India), LEO Pharma A/S (Denmark), Aspen Holdings (South Africa), Sanofi (France).
In June 2023, Bayer Biological Ltd (BE) received FDA approval in The United States, for the LMWH (enoxaparin sodium) single-chamber syringes for prophylaxis of deep vein thrombosis for various surgeries and conditions.
Segmentation Table
Attribute Details
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 4.4% from 2024-2032
Unit Value (USD billion)
Segmentation
By Product
Unfractionated Heparin (UFH)
Low Molecular Weight Heparin (LMWH)
By Source
Bovine
Porcine
By Application
Deep Vein Thrombosis & Pulmonary Embolism
Atrial Fibrillation
Heart Attacks
Stroke
Others
By Route of Administration
Intravenous Infusion
Subcutaneous Injection
By End-user
Hospitals & ASCs
Clinics
Others
By Region
North America (By Product, By Source, By Application, By Route of Administration, By End-user, By Country)
- U.S.
- Canada
Europe (By Product, By Source, By Application, By Route of Administration, By End-user, By Country/Sub-Region)
- U.K.
- Germany
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
Asia Pacific (By Product, By Source, By Application, By Route of Administration, By End-user, By Country/Sub-Region)
- Japan
- China
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
Latin America (By Product, By Source, By Application, By Route of Administration, By End-user, By Country/Sub-Region)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa (By Product, By Source, By Application, By Route of Administration, By End-user, By Country/Sub-Region)
- GCC
- South Africa
- Rest of Middle East & Africa
Please Note: It will take 2-3 business days to complete the report upon order confirmation.
Table of Contents
200 Pages
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Key Industry Developments -Mergers, Acquisitions, and Partnerships
- 4.2. New Product Launches, By Key Players
- 4.3. Prevalence of Key Cardiovascular Diseases, By Key Countries
- 4.4. Blood Clots: Stats & Facts
- 4.5. Overview of Technological Advancements in Heparin
- 4.6. Impact of COVID-19 on the Global Heparin Market
- 4.7. Regulatory Scenario by Key Countries/ Region
- 4.8. Reimbursement Scenario by Key Countries/ Region
- 4.9. China Heparin Market Overview (Production/ Supply Impacted by Swine
- 5. Fever, etc.)
- 5.1. Pricing Analysis of Heparin
- 6. Global Heparin Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast – By Product
- 6.1.1. Unfractionated Heparin (UFH)
- 6.1.2. Low Molecular Weight Heparin (LMWH)
- 6.2. Market Analysis, Insights and Forecast – By Source
- 6.2.1. Bovine
- 6.2.2. Porcine
- 6.3. Market Analysis, Insights and Forecast – By Application
- 6.3.1. Deep Vein Thrombosis & Pulmonary Embolism
- 6.3.2. Atrial Fibrillation
- 6.3.3. Heart Attacks
- 6.3.4. Stroke
- 6.3.5. Others
- 6.4. Market Analysis, Insights and Forecast – By Route of Administration
- 6.4.1. Intravenous Infusion
- 6.4.2. Subcutaneous Injection
- 6.5. Market Analysis, Insights and Forecast – By End-User
- 6.5.1. Hospitals & ASCs
- 6.5.2. Clinics
- 6.5.3. Others
- 6.6. Market Analysis, Insights and Forecast – By Region
- 6.6.1. North America
- 6.6.2. Europe
- 6.6.3. Asia Pacific
- 6.6.4. Latin America
- 6.6.5. Middle East & Africa
- 7. North America Heparin Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast – By Product
- 7.1.1. Unfractionated Heparin (UFH)
- 7.1.2. Low Molecular Weight Heparin (LMWH)
- 7.2. Market Analysis, Insights and Forecast – By Source
- 7.2.1. Bovine
- 7.2.2. Porcine
- 7.3. Market Analysis, Insights and Forecast – By Application
- 7.3.1. Deep Vein Thrombosis & Pulmonary Embolism
- 7.3.2. Atrial Fibrillation
- 7.3.3. Heart Attacks
- 7.3.4. Stroke
- 7.3.5. Others
- 7.4. Market Analysis, Insights and Forecast – By Route of Administration
- 7.4.1. Intravenous Infusion
- 7.4.2. Subcutaneous Injection
- 7.5. Market Analysis, Insights and Forecast – By End-User
- 7.5.1. Hospitals & ASCs
- 7.5.2. Clinics
- 7.5.3. Others
- 7.6. Market Analysis, Insights and Forecast – By Country
- 7.6.1. U.S.
- 7.6.2. Canada
- 8. Europe Heparin Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast – By Product
- 8.1.1. Unfractionated Heparin (UFH)
- 8.1.2. Low Molecular Weight Heparin (LMWH)
- 8.2. Market Analysis, Insights and Forecast – By Source
- 8.2.1. Bovine
- 8.2.2. Porcine
- 8.3. Market Analysis, Insights and Forecast – By Application
- 8.3.1. Deep Vein Thrombosis & Pulmonary Embolism
- 8.3.2. Atrial Fibrillation
- 8.3.3. Heart Attacks
- 8.3.4. Stroke
- 8.3.5. Others
- 8.4. Market Analysis, Insights and Forecast – By Route of Administration
- 8.4.1. Intravenous Infusion
- 8.4.2. Subcutaneous Injection
- 8.5. Market Analysis, Insights and Forecast – By End-User
- 8.5.1. Hospitals & ASCs
- 8.5.2. Clinics
- 8.5.3. Others
- 8.6. Market Analysis, Insights and Forecast – By Country/Sub-region
- 8.6.1. U.K.
- 8.6.2. Germany
- 8.6.3. France
- 8.6.4. Italy
- 8.6.5. Spain
- 8.6.6. Scandinavia
- 8.6.7. Rest of Europe
- 9. Asia Pacific Heparin Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast – By Product
- 9.1.1. Unfractionated Heparin (UFH)
- 9.1.2. Low Molecular Weight Heparin (LMWH)
- 9.2. Market Analysis, Insights and Forecast – By Source
- 9.2.1. Bovine
- 9.2.2. Porcine
- 9.3. Market Analysis, Insights and Forecast – By Application
- 9.3.1. Deep Vein Thrombosis & Pulmonary Embolism
- 9.3.2. Atrial Fibrillation
- 9.3.3. Heart Attacks
- 9.3.4. Stroke
- 9.3.5. Others
- 9.4. Market Analysis, Insights and Forecast – By Route of Administration
- 9.4.1. Intravenous Infusion
- 9.4.2. Subcutaneous Injection
- 9.5. Market Analysis, Insights and Forecast – By End-User
- 9.5.1. Hospitals & ASCs
- 9.5.2. Clinics
- 9.5.3. Others
- 9.6. Market Analysis, Insights and Forecast – By Country/Sub-region
- 9.6.1. Japan
- 9.6.2. China
- 9.6.3. India
- 9.6.4. Australia
- 9.6.5. Southeast Asia
- 9.6.6. Rest of Asia Pacific
- 10. Latin America Heparin Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast – By Product
- 10.1.1. Unfractionated Heparin (UFH)
- 10.1.2. Low Molecular Weight Heparin (LMWH)
- 10.2. Market Analysis, Insights and Forecast – By Source
- 10.2.1. Bovine
- 10.2.2. Porcine
- 10.3. Market Analysis, Insights and Forecast – By Application
- 10.3.1. Deep Vein Thrombosis & Pulmonary Embolism
- 10.3.2. Atrial Fibrillation
- 10.3.3. Heart Attacks
- 10.3.4. Stroke
- 10.3.5. Others
- 10.4. Market Analysis, Insights and Forecast – By Route of Administration
- 10.4.1. Intravenous Infusion
- 10.4.2. Subcutaneous Injection
- 10.5. Market Analysis, Insights and Forecast – By End-User
- 10.5.1. Hospitals & ASCs
- 10.5.2. Clinics
- 10.5.3. Others
- 10.6. Market Analysis, Insights and Forecast – By Country/Sub-region
- 10.6.1. Brazil
- 10.6.2. Mexico
- 10.6.3. Rest of Latin America
- 11. Middle East & Africa Heparin Market Analysis, Insights and Forecast, 2019-2032
- 11.1. Market Analysis, Insights and Forecast – By Product
- 11.1.1. Unfractionated Heparin (UFH)
- 11.1.2. Low Molecular Weight Heparin (LMWH)
- 11.2. Market Analysis, Insights and Forecast – By Source
- 11.2.1. Bovine
- 11.2.2. Porcine
- 11.3. Market Analysis, Insights and Forecast – By Application
- 11.3.1. Deep Vein Thrombosis & Pulmonary Embolism
- 11.3.2. Atrial Fibrillation
- 11.3.3. Heart Attacks
- 11.3.4. Stroke
- 11.3.5. Others
- 11.4. Market Analysis, Insights and Forecast – By Route of Administration
- 11.4.1. Intravenous Infusion
- 11.4.2. Subcutaneous Injection
- 11.5. Market Analysis, Insights and Forecast – By End-User
- 11.5.1. Hospitals & ASCs
- 11.5.2. Clinics
- 11.5.3. Others
- 11.6. Market Analysis, Insights and Forecast – By Country/Sub-region
- 11.6.1. South Africa
- 11.6.2. GCC
- 11.6.3. Rest of Middle East & Africa
- 12. Competitive Analysis
- 12.1. Global Market Share Analysis (2023)
- 12.2. Company Profiles
- 12.2.1. Opocrin S.p.A.
- 12.2.1.1. Overview
- 12.2.1.2. Products & Services
- 12.2.1.3. SWOT Analysis
- 12.2.1.4. Recent Developments
- 12.2.1.5. Strategies
- 12.2.1.6. Financials (Based on Availability)
- 12.2.2. Baxter
- 12.2.2.1. Overview
- 12.2.2.2. Products & Services
- 12.2.2.3. SWOT Analysis
- 12.2.2.4. Recent Developments
- 12.2.2.5. Strategies
- 12.2.2.6. Financials (Based on Availability)
- 12.2.3. Pfizer Inc.
- 12.2.3.1. Overview
- 12.2.3.2. Products & Services
- 12.2.3.3. SWOT Analysis
- 12.2.3.4. Recent Developments
- 12.2.3.5. Strategies
- 12.2.3.6. Financials (Based on Availability)
- 12.2.4. Bioiberica S.A.U.
- 12.2.4.1. Overview
- 12.2.4.2. Products & Services
- 12.2.4.3. SWOT Analysis
- 12.2.4.4. Recent Developments
- 12.2.4.5. Strategies
- 12.2.4.6. Financials (Based on Availability)
- 12.2.5. Fresenius SE & Co. KgaA
- 12.2.5.1. Overview
- 12.2.5.2. Products & Services
- 12.2.5.3. SWOT Analysis
- 12.2.5.4. Recent Developments
- 12.2.5.5. Strategies
- 12.2.5.6. Financials (Based on Availability)
- 12.2.6. Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
- 12.2.6.1. Overview
- 12.2.6.2. Products & Services
- 12.2.6.3. SWOT Analysis
- 12.2.6.4. Recent Developments
- 12.2.6.5. Strategies
- 12.2.6.6. Financials (Based on Availability)
- 12.2.7. B. Braun SE
- 12.2.7.1. Overview
- 12.2.7.2. Products & Services
- 12.2.7.3. SWOT Analysis
- 12.2.7.4. Recent Developments
- 12.2.7.5. Strategies
- 12.2.7.6. Financials (Based on Availability)
- 12.2.8. Dr. Reddy’s Laboratories Ltd.
- 12.2.8.1. Overview
- 12.2.8.2. Products & Services
- 12.2.8.3. SWOT Analysis
- 12.2.8.4. Recent Developments
- 12.2.8.5. Strategies
- 12.2.8.6. Financials (Based on Availability)
- 12.2.9. LEO Pharma A/S
- 12.2.9.1. Overview
- 12.2.9.2. Products & Services
- 12.2.9.3. SWOT Analysis
- 12.2.9.4. Recent Developments
- 12.2.9.5. Strategies
- 12.2.9.6. Financials (Based on Availability)
- 12.2.10. Aspen Holdings
- 12.2.10.1. Overview
- 12.2.10.2. Products & Services
- 12.2.10.3. SWOT Analysis
- 12.2.10.4. Recent Developments
- 12.2.10.5. Strategies
- 12.2.10.6. Financials (Based on Availability)
- 12.2.11. Sanofi
- 12.2.11.1. Overview
- 12.2.11.2. Products & Services
- 12.2.11.3. SWOT Analysis
- 12.2.11.4. Recent Developments
- 12.2.11.5. Strategies
- 12.2.11.6. Financials (Based on Availability)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
